Jade Biosciences (JBIO) Other Accumulated Expenses (2020 - 2025)
Jade Biosciences (JBIO) posted Other Accumulated Expenses of $429000.0 for Q1 2025, up 34.48% on a QoQ basis from $319000.0 in Q4 2024, and down 36.35% year-over-year from $674000.0 in Q1 2024.
Jade Biosciences (JBIO) Other Accumulated Expenses (2020 - 2025) Analysis & Trends
Jade Biosciences' Other Accumulated Expenses history runs 6 years deep, the most recent figure standing at $429000.0 for Q1 2025.
- Quarterly Other Accumulated Expenses fell 36.35% year-over-year to $429000.0 in Q1 2025, while the trailing twelve-month figure through Mar 2025 was $429000.0 (down 36.35% YoY) and the FY2024 annual result came in at $319000.0, down 70.73% from the prior year.
- Other Accumulated Expenses was $429000.0 for Q1 2025 at Jade Biosciences, up from $319000.0 in the prior quarter.
- Across five years, Other Accumulated Expenses topped out at $1.1 million in Q4 2023 and bottomed at $120000.0 in Q2 2021.
- A 5-year average of $388500.0 and a median of $305500.0 in 2024 frame the typical range for Other Accumulated Expenses.
- Annual changes were most pronounced in 2021 — Other Accumulated Expenses jumped 694.44% — and 2024, when it plunged 70.73%.
- Jade Biosciences' Other Accumulated Expenses stood at $143000.0 in 2021, then jumped by 165.73% to $380000.0 in 2022, then jumped by 186.84% to $1.1 million in 2023, then plunged by 70.73% to $319000.0 in 2024, then surged by 34.48% to $429000.0 in 2025.
- Business Quant data shows JBIO's Other Accumulated Expenses at $429000.0 in Q1 2025, $319000.0 in Q4 2024, and $292000.0 in Q3 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,861.65 Bn | 66,861.36 Bn | - |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.72 Bn | - |
| 3 | Akari Therapeutics | 1,071.19 Bn | 1,071.19 Bn | - |
| 4 | BeOne Medicines | 469.11 Bn | 464.32 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 123.03 Bn | 115.78 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.13 Bn | 61.37 Bn | 3.31 Bn |
| 7 | Belite Bio | 63.44 Bn | 63.44 Bn | - |
| 8 | Argenx Se | 55.97 Bn | 50.78 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.53 Bn | 34.52 Bn | 959.66 Mn |
| 10 | Jade Biosciences | 1.17 Bn | 861.00 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 429,000.00 |
| Dec 31, 2024 | 319,000.00 |
| Sep 30, 2024 | 292,000.00 |
| Jun 30, 2024 | 669,000.00 |
| Mar 31, 2024 | 674,000.00 |
| Dec 31, 2023 | 1.09 Mn |
| Sep 30, 2023 | 439,000.00 |
| Jun 30, 2023 | 583,000.00 |
| Mar 31, 2023 | 252,000.00 |
| Dec 31, 2022 | 380,000.00 |
| Sep 30, 2022 | 254,000.00 |
| Jun 30, 2022 | 151,000.00 |
| Mar 31, 2022 | 241,000.00 |
| Dec 31, 2021 | 143,000.00 |
| Sep 30, 2021 | 180,000.00 |
| Jun 30, 2021 | 120,000.00 |
| Dec 31, 2020 | 18,000.00 |